Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 14/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397162 | 0.95 | CNR2 (0.46) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL1587367 | 0.93 | CNR2 (0.45) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL1587867 | 0.93 | CNR2 (0.45) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL1587368 | 0.93 | CNR2 (0.45) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL12795998 | 0.87 | MAPT (0.51) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL3770097 | 0.85 | CDK2 (0.46) | HDAC1CNR2MAPK1MAPK3 | |
| SCHEMBL10145297 | 0.85 | CNR2 (0.49) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL10145847 | 0.83 | CDK1 (0.48) | HDAC1MAPK1 | |
| Hydrochloric Acid SCHEMBL541457 | 0.82 | CDK1 (0.48) | HDAC1MAPK1 | |
| SCHEMBL24348347 | 0.81 | MAPK1 (0.42) | HDAC3HDAC1HDAC2HDAC6CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2010113834-A1 | PYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | HDAC3 2151/4885HDAC1 3139/4885HDAC2 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.